NYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis → Millionaire-Making “Wealth Pattern” Just Repeated on April 22 (From Paradigm Press) (Ad) Free HIMS Stock Alerts $20.78 -0.79 (-3.66%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$20.70▼$21.9550-Day Range$11.25▼$21.7552-Week Range$5.65▼$21.95Volume9.72 million shsAverage Volume6.84 million shsMarket Capitalization$4.46 billionP/E RatioN/ADividend YieldN/APrice Target$16.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Hims & Hers Health alerts: Email Address Hims & Hers Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside22.3% Downside$16.14 Price TargetShort InterestBearish14.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 29 Articles This WeekInsider TradingSelling Shares$15.08 M Sold Last QuarterProj. Earnings Growth83.33%From $0.18 to $0.33 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.19 out of 5 starsMedical Sector512th out of 905 stocksOffices & Clinics Of Medical Doctors Industry5th out of 6 stocks 2.3 Analyst's Opinion Consensus RatingHims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 9 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageHims & Hers Health has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Hims & Hers Health's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.69% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 20.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HIMS. Previous Next 3.1 News and Social Media Coverage News SentimentHims & Hers Health has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Hims & Hers Health this week, compared to 8 articles on an average week.Search Interest82 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 148% compared to the previous 30 days.MarketBeat Follows54 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 170% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,080,170.00 in company stock.Percentage Held by Insiders17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hims & Hers Health's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Hims & Hers Health are expected to grow by 83.33% in the coming year, from $0.18 to $0.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -2,078.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -2,078.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 12.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Hims & Hers Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… About Hims & Hers Health Stock (NYSE:HIMS)Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.Read More HIMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIMS Stock News HeadlinesJune 6 at 7:34 AM | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 17,625 SharesJune 6 at 7:00 AM | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 188,888 SharesJune 3, 2024 | marketbeat.comHims & Hers Health Soars on Generic GLP-1 Rollout PlansHim & Hers Health Inc. NYSE: HIMS provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through brand and generic versions of Pfizer Inc. NYSE: PFE Viagra (Sildenafil) and Eli Lilly & Co. NYSE: LLY Cialis (Tadalafil).June 3, 2024 | marketbeat.comHims & Hers Health Soars on Generic GLP-1 Rollout Plans Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatmentsMay 31, 2024 | insidertrades.comSoleil Boughton Sells 2,502 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockMay 30, 2024 | marketbeat.comCall Option Volumes Spiked For These 3 StocksAs the saying goes, always follow the money. This time, investors can follow the proverbial big players through an options activity screener, spotting unusual trends in how markets are betting.May 30, 2024 | marketbeat.comCall Option Volumes Spiked For These 3 Stocks (HIMS)Option traders decided to plow into call contracts for these three stocks, investors can see the specific fundamental reasons behind this decisionMay 28, 2024 | marketbeat.comLifeMD Can Surge on Its GLP-1 Offerings (HIMS)LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a resultMay 22, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $98,349.15 in StockMay 21, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) Insider Irene Becklund Sells 943 SharesJune 7 at 7:58 AM | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Sets New 52-Week High at $21.55June 7 at 1:16 AM | americanbankingnews.comHims & Hers Health Target of Unusually Large Options Trading (NYSE:HIMS)June 6 at 4:32 AM | americanbankingnews.comInsider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $2,664,656.85 in StockJune 5 at 2:20 AM | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Stock Price Down 1.2% Following Insider SellingJune 4, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Price Target Increased to $22.00 by Analysts at Bank of AmericaJune 4, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Trading 6.5% Higher on Analyst UpgradeJune 2, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Trading Down 2.7%June 2, 2024 | americanbankingnews.comHims & Hers Health, Inc. (NYSE:HIMS) Sees Significant Increase in Short InterestJune 2, 2024 | americanbankingnews.comBrokerages Set Hims & Hers Health, Inc. (NYSE:HIMS) Price Target at $15.69June 1, 2024 | fool.comHims & Hers Health Stock Soared This Week: Here's WhyJune 1, 2024 | americanbankingnews.comFinancial Comparison: Hims & Hers Health (NYSE:HIMS) and Auna (NYSE:AUNA)May 29, 2024 | benzinga.comSmart Money Is Betting Big In HIMS OptionsMay 26, 2024 | fool.comThe Ultimate Growth Stock to Buy With $20 Right NowMay 24, 2024 | theglobeandmail.comIs Hims & Hers Stock a Buy for GLP-1 Upside?May 24, 2024 | investorplace.com7 Stocks to Dominate in the Next Economic UpturnSee More Headlines Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today6/07/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryN/A Current SymbolNYSE:HIMS CUSIPN/A CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees1,046Year FoundedN/APrice Target and Rating Average Stock Price Target$16.14 High Stock Price Target$24.00 Low Stock Price Target$10.00 Potential Upside/Downside-22.3%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio115.44 P/E GrowthN/ANet Income$-23,550,000.00 Net Margins-0.24% Pretax Margin0.05% Return on Equity-0.70% Return on Assets-0.55% Debt Debt-to-Equity RatioN/A Current Ratio2.80 Quick Ratio2.48 Sales & Book Value Annual Sales$872 million Price / Sales5.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book12.91Miscellaneous Outstanding Shares214,790,000Free Float176,747,000Market Cap$4.46 billion OptionableOptionable Beta1.08 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Andrew Dudum (Age 35)Co-Founder, Chairman & CEO Comp: $1.98MMr. Yemi Okupe (Age 38)Chief Financial Officer Comp: $1.01MMs. Melissa Baird (Age 46)Chief Operating Officer Comp: $1.05MMs. Soleil Teubner Boughton (Age 45)Chief Legal Officer & Corporate Secretary Comp: $928.7kDr. Patrick Carroll M.D. (Age 66)Chief Medical Officer, Member of Medical Advisory Board & Director Comp: $54kMr. Mike Chi (Age 44)Chief Commercial Officer Comp: $998kMs. Irene A. Becklund (Age 39)Senior VP, Controller & Principal Accounting Officer Comp: $361.12kMs. Khobi BrooklynChief Communications OfficerMs. Amee ParekhSenior Vice President of Human ResourcesDr. Peter Stahl M.D.Senior VP & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsTeladoc HealthNYSE:TDOCAunaNYSE:AUNALifeMDNASDAQ:LFMDAirSculpt TechnologiesNASDAQ:AIRSSHL TelemedicineNASDAQ:SHLTView All CompetitorsInsiders & InstitutionsMelissa BairdSold 17,625 sharesTotal: $359,902.50 ($20.42/share)Andrew DudumSold 188,888 sharesTotal: $3.76 M ($19.88/share)Soleil BoughtonSold 129,667 sharesTotal: $2.66 M ($20.55/share)Soleil BoughtonSold 2,502 sharesTotal: $43,359.66 ($17.33/share)Farallon Capital Management LLCBought 1,634,000 shares on 5/24/2024Ownership: 0.780%View All Insider TransactionsView All Institutional Transactions HIMS Stock Analysis - Frequently Asked Questions Should I buy or sell Hims & Hers Health stock right now? 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last year. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares. View HIMS analyst ratings or view top-rated stocks. What is Hims & Hers Health's stock price target for 2024? 16 analysts have issued twelve-month price targets for Hims & Hers Health's stock. Their HIMS share price targets range from $10.00 to $24.00. On average, they expect the company's stock price to reach $16.14 in the next year. This suggests that the stock has a possible downside of 22.3%. View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts. How have HIMS shares performed in 2024? Hims & Hers Health's stock was trading at $8.90 on January 1st, 2024. Since then, HIMS shares have increased by 133.5% and is now trading at $20.78. View the best growth stocks for 2024 here. Are investors shorting Hims & Hers Health? Hims & Hers Health saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 22,130,000 shares, an increase of 20.3% from the April 30th total of 18,390,000 shares. Based on an average daily volume of 8,300,000 shares, the short-interest ratio is presently 2.7 days. Approximately 14.7% of the shares of the stock are short sold. View Hims & Hers Health's Short Interest. When is Hims & Hers Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our HIMS earnings forecast. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings results on Monday, May, 6th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative trailing twelve-month return on equity of 0.70%. The firm's quarterly revenue was up 45.8% compared to the same quarter last year. During the same period last year, the business earned ($0.05) earnings per share. What ETFs hold Hims & Hers Health's stock? ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include Amplify Online Retail ETF (IBUY), Global X Telemedicine & Digital Health ETF (EDOC), SPDR S&P Health Care Services ETF (XHS), Fidelity Digital Health ETF (FDHT), iShares Virtual Work and Life Multisector ETF (IWFH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and First Trust Small Cap Growth AlphaDEX Fund (FYC). What guidance has Hims & Hers Health issued on next quarter's earnings? Hims & Hers Health updated its second quarter 2024 earnings guidance on Monday, May, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $292.0 million-$297.0 million, compared to the consensus revenue estimate of $288.1 million. Who are Hims & Hers Health's major shareholders? Hims & Hers Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.68%), Institutional Venture Management XVI LLC (2.43%), Institutional Venture Management XV LLC (2.43%), Redpoint Management LLC (2.36%), Farallon Capital Management LLC (0.78%) and Mckinley Capital Management LLC (0.30%). Insiders that own company stock include Alex Bard, Andrew Dudum, Christiane Pendarvis, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:HIMS) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hims & Hers Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.